TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.380
+0.050 (1.15%)
Jul 29, 2026, 4:00 PM EDT - Market closed
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, TriSalus Life Sciences stock has a consensus rating of "Strong Buy" and an average price target of $9.00. The average 1-year stock price forecast is 105.48% higher than the current stock price, while the lowest is $7.00 (+59.82%) and the highest is $11 (+151.14%).
Price Target: $9.00 (+105.48%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 25, 2026.
Analyst Ratings
The average analyst rating for TriSalus Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Buy Reiterates $8 | Buy | Reiterates | $8 | +82.65% | Jun 25, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $7 | Buy | Maintains | $7 | +59.82% | Jun 25, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $10 | Buy | Reiterates | $10 | +128.31% | May 14, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $11 | Buy | Reiterates | $11 | +151.14% | May 13, 2026 |
| Northland Securities | Northland Securities | Buy Reiterates $13 → $8 | Buy | Reiterates | $13 → $8 | +82.65% | Mar 23, 2026 |
Financial Forecast
Revenue This Year
52.40M
from 45.15M
Increased by 16.05%
Revenue Next Year
79.26M
from 52.40M
Increased by 51.28%
EPS This Year
-0.45
EPS Next Year
-0.25
from -0.45
EPS and Forward PE are based on non-GAAP adjusted numbers.